Company profile

Advanced BioDesign

Privately held: no public share price (Privately held French oncology biotech backed by Xerys Invest; no IPO or ticker found. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.a-biodesign.com/news/69-advanced-biodesign-winner-of-the-france-2030-plan-s-call-for-i-demo-projects-to-finance-its-odyssey-clinical-trial-with-up-to-3m.html]) · France

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
ABD-3001
Phase 2
ALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.